Navigation Links
Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Date:9/5/2011

AMSTERDAM, September 6, 2011 /PRNewswire/ --


Gains US Patent Protection for Proprietary AAV Intellectual Property

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications. This agreement expands on an original non-exclusive license for AAV5 from the NIH. Financial details of the agreement have not been disclosed.

Concurrent with the signing of this exclusive license, AMT has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "AAV vectors produced in insect cells", which covers a core asset of the Company's proprietary manufacturing technology. This patent comprises a novel and significantly improved method of delivery of therapeutic genes to targets using adeno-associated viral (AAV) derived vectors produced in insect cells. The technology has already been successfully applied to Glybera®, a gene therapy for lipoprotein lipase deficiency (LPLD). AMT believes this intellectual property together with the NIH exclusive license places the Company in a unique position for a number of AAV serotype 5-based programs, including hemophilia, acute intermittent prophyria, GDNF-related diseases and Sanfilippo B.

"This expansion of our existing AAV5 license with NIH is an important addition to our intellectual property position as it supports several of our pipeline products that follow Glybera. The granting of an exclusive license by the NIH is very unusual and we believe acknowledges AMT's status in the gene therapy sector," stated Jörn Aldag, CEO of AMT. "As well as continuing to work diligently towards the re-examination of Glybera registration dossier, we also appreciate the significant valu
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Molecular sleuths track evolution through the ribosome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... (PRWEB) November 25, 2014 Whitehouse ... officially joined the Morris County (New Jersey) Chamber ... is a leading business organization in the North ... to further engage some key clients in the ... in the geographic area. Membership enables Whitehouse Laboratories ...
(Date:11/26/2014)... Global biostimulants market is expected to reach ... CAGR of 12.5%. In order to cater to ... ecological impacts, farmers are looking to adopt natural ... more effectively & efficiently. Biostimulants are consequently seen ... on investments. , Leading companies in the biostimulants ...
(Date:11/26/2014)... 25 novembre 2014 Theravalues Corporation est fier ... marché européen au salon Hi Europe 2014 (du ... ). Curcumine la plus biodisponible actuellement ... (non-cristalline) à des ingrédients approuvés par les règlements ... jaune présent dans la racine de curcuma ( ...
(Date:11/24/2014)... UAE, November 24, 2014 Five ... Bin Rashid Al Maktoum Awards for Medical Sciences", in ... Dubai, United Arab Emirates , on 15 December ... , The Carter Center which won the ... actively involved in numerous programs that aim to improve ...
Breaking Biology Technology:Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3Five US Winners Among Recipients of Hamdan Medical Awards 2
... Omaxe Infrastructure &,Construction Private Ltd(OICPL), a wholly owned subsidiary ... the construction of Allopathic Medical,College and Associated Hospital at ... value of the project is Rs250 crores,approx., The ... with total built up area,of 15.66 lac sq ft. ...
... initial listing requirements with NASDAQ; Stock Symbol ... extends cash runway while focusing on ... 21 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals, Inc. (formerly Sonus ... announced that the Company has completed its ...
... SHANGHAI, China, Aug. 21 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, ... "the,Company"), a leading Chinese firm specializing ... distribution of probiotics products,today announced it ... Square,Pharmaceutical Co., Ltd. ("Square Pharmaceutical") to ...
Cached Biology Technology:Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores 2Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 2Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 3Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 4Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 5Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 6China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 2China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 3
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... of scientists led by Fred Hutchinson Cancer Research Center ... feasibility of large-scale, standardized protein measurements, which are necessary ... The study, to be published Dec. 8 online in ... scientists, targeted protein-detection approach has the potential to systematically ...
... even a mild traumatic brain injury. While the brain may ... suggest that the brain,s protective coverings may feel the ... mouse trauma model, senior author Dorian McGavern, Ph.D., scientist at ... of the National Institutes of Health, watched specific cells mount ...
... Philadelphia have manipulated key biological events in adult blood ... after the newborn period. Because this fetal hemoglobin is ... (SCD), the cell culture findings may open the door ... "Our study shows the power of a ...
Cached Biology News:Novel method could help bring cancer biomarkers to clinic 2Novel method could help bring cancer biomarkers to clinic 3Concussion secrets unveiled in mice and people 2Concussion secrets unveiled in mice and people 3Flipping a gene switch reactivates fetal hemoglobin, may reverse sickle cell disease 2